文献速递间质性肺疾病

基因组学整合进纤维化间质性肺疾病管理

Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.
PubMed 文献 · Chest · 2019-01-17

综述指出基因组学在纤维化间质性肺疾病(ILD)易感性和进展机制中起重要作用。MUC5B启动子多态性与间质性异常相关,TERT、TERC、SFTPC、DKC1等罕见变异见于家族性间质性肺炎且常伴普通型间质性肺炎模式。端粒缩短及端粒生物学相关基因突变与疾病进展、肺功能和生存相关,理解遗传风险有助于个体化治疗。

要点

  • MUC5B启动子多态性是与间质性异常相关的常见基因变异。
  • TERT、TERC、SFTPC、DKC1等罕见变异见于家族性间质性肺炎。
  • 端粒缩短和端粒相关基因突变与疾病进展、肺功能和生存相关。

核心结论

  • 基因组学在纤维化ILD易感性和进展机制中起重要作用,理解遗传风险有助于个体化治疗选择。

研究设计与样本

  • 综述,未报告检索范围。

主要发现

  • 间质性异常与MUC5B启动子多态性(常见基因变异)一致相关。
  • TERT、TERC、SFTPC和DKC1等罕见基因变异突变可见于家族性间质性肺炎患者,且常与普通型间质性肺炎纤维化模式相关。
  • MUC5B rs35705950基因型的次要等位基因在多种散发性ILD中常见,包括特发性肺纤维化和慢性过敏性肺炎。
  • 家族性肺纤维化相关基因突变可见于结缔组织病相关ILD患者,如类风湿关节炎相关ILD。
  • 家族性和散发性ILD中均可见端粒缩短和端粒生物学相关基因突变,对疾病进展、肺功能和生存有重要意义。

临床怎么用

  • 对纤维化ILD患者,可考虑基因组风险因素评估以辅助判断疾病进展和个体化治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibrotic interstitial lung diseases (ILDs) have a high mortality rate with an unpredictable disease course and clinical features that frequently overlap. Recent data indicate important roles for genomics in the mechanisms underlying susceptibility and progression of pulmonary fibrosis. The impact of these genomic markers on pharmacotherapy and their contribution to outcomes is increasingly recognized. Interstitial lung abnormalities, frequently considered representative of early ILD, have been consistently associated with the MUC5B promoter polymorphism, a common gene variant. Other rare gene variant mutations, including TERT, TERC, SFTPC, and DKC1, may be present in patients with familial interstitial pneumonia and are frequently associated with a usual interstitial pneumonia pattern of fibrosis. The minor allele of the MUC5B rs35705950 genotype is prevalent in several sporadic forms of ILD, including idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Gene mutations that characterize familial pulmonary fibrosis may be present in patients with connective tissue disease-related ILD, such as rheumatoid arthritis-ILD. Additionally, shorter telomere lengths and mutations in telomere biology-related genes have been demonstrated in both familial and sporadic ILD, with significant implications for disease progression, lung function, and survival. An improved understanding of the impact of genetic and genomic risk factors on disease progression would better guide personalized therapeutic choices in persons with fibrotic ILD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Adegunsoye A, Vij R, Noth I, et al. Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease. Chest. 2019. PMID: 30660786. doi:10.1016/j.chest.2018.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。